Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals Breastfeeding

Modern medicine has evolved so much so that sooner or later every breastfeeding mother needs to take it in one form or other. Medication that is present in mothers blood will transfer into her breast milk to some extent. Most drugs do so at low levels and pose no real risk to infants but then there are some exceptions. In This post will discuss whether Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals is safe in breast-feeding or not.

What is Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals used for?


Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for: Short-Term Treatment of Active Duodenal Ulcer ( 1.1) H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ( 1.2) Maintenance of Healed Duodenal Ulcers ( 1.3) Short-Term Treatment of Active Benign Gastric Ulcer ( 1.4) Healing of nonsteroidal anti-inflammatory drugs (NSAID)-Associated Gastric Ulcer ( 1.5) Risk Reduction of NSAID-Associated Gastric Ulcer ( 1.6) Gastroesophageal Reflux Disease (GERD) ( 1.7) Maintenance of Healing of Erosive Esophagitis (EE) ( 1.8) Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES) ( 1.9) 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules/amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin prescribing information, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole delayed-release capsules are indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see Clinical Studies (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole delayed-release capsules are indicated for short-term treatment (up to eight weeks) for healing and symptom relief of active benign gastric ulcer [see Clinical Studies (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole delayed-release capsules are indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond eight weeks [see Clinical Studies (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole delayed-release capsules are indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see Clinical Studies (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to eight weeks [see Clinical Studies (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole delayed-release capsules are indicated for short-term treatment (up to eight weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with lansoprazole delayed-release capsules for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment. If there is a recurrence of erosive esophagitis an additional eight week course of lansoprazole delayed-release capsules may be considered [see Clinical Studies (14)] . 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole delayed-release capsules are indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see Clinical Studies (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES) Lansoprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see Clinical Studies (14)].

Can I continue breastfeeding if I am using Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals? How long does it stays in breast milk?

Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals safe for breastfeeding
As per our analysis Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals contains only one ingredient and that is Lansoprazole. We have analyzed Lansoprazole and it seems to be safe to use Lansoprazole while breastfeeding, that means usage of Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals shall be safe while breastfeeding. Below you can check more details of Lansoprazole usage in breastfeeding. We recommend you to go through provided detailed analysis as below take decision accordingly.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers Lansoprazole or its metabolites are excreted in the milk of rats. It is not known whether lansoprazole is excreted in human milk. Because many drugs are excreted in human milk, because of the potential for serious adverse reactions in nursing infants from lansoprazole, and because of the potential for tumorigenicity shown for lansoprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue lansoprazole, taking into account the importance of lansoprazole to the mother.

Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals Breastfeeding Analsys


Lansoprazole while Breastfeeding

Safe

CAS Number: 103577-45-3

At latest update, relevant information on excretion into breast milk was not found. Due to a high serum-protein-binding capacity, excretion of Lansoprazole into breast milk is non-significant. Since it's neutralized by the acid pH of stomach, capsules with enteric coated granules are used. Because of this, it is thought that the small quantity of Lansoprazole that may reach the breast milk would be neutralized by infant's stomach. In addition, absorption is greatly decreased by the presence of food. Both Omeprazole and Pantoprazole pertain to the same chemical group with similar pharmacokinetics that are excreted in non-significant amount into the breast milk. Medication that has been used for treatment of newborn and premature infants. Hyperprolactinemia and galactorrhea have been reported by the use of such medication, though some authors have failed to show the same findings.


Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals Breastfeeding Analsys - 2


Lansoprazole while Breastfeeding

CAS Number: 103577-45-3

No information is available on the use of lansoprazole during breastfeeding. However, lansoprazole has been used safely in newborn infants, so it is unlikely that the amount in breastmilk would be harmful.


Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals and breastfeeding

I am nursing mother and I have already used Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals, what should I do?

Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals is safe in breastfeeding and should not create any health problem for your baby but in case you feel any health issue associated with Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals you should contact your doctor or health care provider. Be it pregnancy or lactation you shall keep your doctor informed.


My doctor has prescribed me Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals, what should I do?

Definitely, Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals is safe in lactation for baby. No wonder your doctor has recommended it.


If I am using Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals, will my baby need extra monitoring?

No extra baby monitoring required while mother is using Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals


Who can I talk to if I have questions about usage of Lansoprazole | Denton Pharma, Inc. Dba Northwind Pharmaceuticals in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week